Les nouveautés 2010 : Les points forts de l'ASCO-GU, EAU, ASCO, AUA…

25 mars 2011

Auteurs : T. Bessede, P. Bigot, Y. Neuzillet, G. Pignot
Référence : Prog Urol, 2011, 21, S16, suppl. S2




 



Le texte complet de cet article est disponible en PDF.
Cliquer ici pour le visualiser



Références



Escudier B., Négrier S., Gravis G., Chevreau C., Delva R., Bay J.O., et al. Can the combination of temsirolimus and bevacizumab improve the treatment of metastatic renal cell carcinoma (mRCC)? Results of the randomized TORAVA phase II trial J Clin Oncol 2010 ;  28 (15s suppl) : Abstract 4516.
Dandamudi U.B., Ghebremichael M.S., Sosman J.A., Regan M.M., Atkins M.B., Clark J., et al. Cytokine Working Group A phase II study of bevacizumab (B) and high-dose aldesleukin (IL-2) in patients (p) with metastatic renal cell carcinoma (mRCC):A Cytokine Working Group Study (CWGS) J Clin Oncol 2010 ;  28 (15s suppl) : Abstract 4530.
McDermott D.F., Ghebremichael M., Signoretti S., Margolin K., Clark J., Sosman J., et al. On behalf of the Cytokine Working Group The high-dose aldesleukin (HD IL-2) Select trial in patients with metastatic renal cell carcinoma (mRCC): Preliminary assessment of clinical benefit J Clin Oncol 2010 ;  28 (15s suppl) : Abstract 321.
Choueiri T.K., Xie W., Kollmannsberger C., North S., Vickers M.M., Knox J.J., et al. The impact of cytoreductive nephrectomy in patients with metastatic renal cell carcinoma (mRCC) treated with vascular endothelial growth factor (VEGF) – targeted therapy J Clin Oncol 2010 ;  28 (15s suppl) : Abstract 311.
Rini B.I., Zhou M., Aydin H., Elson P., Maddala T., Knezevic D., et al. Identification of prognostic genomic markers in patients with localized clear cell renal cell carcinoma (ccRCC) J Clin Oncol 2010 ;  28 (15s suppl) : Abstract 4501.
Tran H.T., Liu Y., Lin Y., Martin A., Baker K.L., Fritsche H.A., et al. VEG102616 Investigators Patients, and Team. Use of a multiplatform analysis of plasma cytokines and angiogenic factors (CAFs) to identify baseline CAFs associated with pazopanib response and tumor burden in renal cell carcinoma (RCC) patients J Clin Oncol 2010 ;  28 (15s suppl) : Abstract 4522.
Heng D., Xie W., Bjarnason G.A., Vaishampayan U.N., Donskov F., Wood L., et al. A unified prognostic model for first – and second-line targeted therapy in metastatic renal cell carcinoma (mRCC): Results from a large international study J Clin Oncol 2010 ;  28 (15s suppl) : Abstract 4523.
Warde P.R. Intergroup randomized phase III study of androgen deprivation therapy (ADT) plus radiation therapy (RT) in locally advanced prostate cancer (CaP) (NCIC-CTG, SWOG, MRC-UK, INT: T94-0110;NCT00002633) 2010 ASCO Annual Meeting, Chicago, June 4–8, 2010 :  (2010). 
28:18s (suppl):Abstract CRA4504.
Mottet N. Impact of radiotherapy (RT) combined with androgen deprivation (ADT) vs ADT alone for local control in clinically locally advanced prostate cancer 2010 ASCO Annual Meeting, Chicago, June 4–8, 2010 :  (2010). 
28:18s (suppl):Abstract CRA 4505.
Huang J. Rates of Secondary Primary Cancers after Definitive Treatment for Prostate Cancer Using Modern Radiation Therapy Techniques. ASTRO 2009 Annual Meeting, Chicago, Nov 1–5 2009:Abstract 2256. acover.wcs%3Fentryid=060254
Van Hemelrijck M. Risk Of Thromboembolic Diseases In Men With Prostate Cancer:Results From The Population-based PCBaSe Sweden 2010 EAU Annual congress, Barcelona, 16–20 avril 2010 :  (2010). 
9:75 Abstract 134.
Gontero P. The role of adjuvant hormonal treatment after surgery for high-risk localized prostate cancer-results of a multi-institutional matched analysis 2010 EAU Annual congress, Barcelona, 16–20 avril 2010 :  (2010). 
9:225 Abstract 686.
Yu E.Y. Dynamics of bone mineral density during intermittent androgen deprivation for men with biochemical recurrence of prostate cancer 2010 ASCO Annual Meeting, Chicago, June 4–8, 2010 :  (2010). 
28:18s (suppl):Abstract CRA 4558.
Fizazi K. A randomized phase III trial of denosumab versus zoledronic acid in patients with bone metastases from castration-resistant prostate cancer 2010 ASCO Annual Meeting, Chicago, June 4–8, 2010 :  (2010). 
28:18s (suppl):Abstract CRA 4507.
De La Rosette J. Evaluation of the efficacy and safety of switching from treatment with leuprolide 1-month dosing regimen to degarelix 1-month dosing regimen in prostate cancer (PCa) patients 2010 EAU Annual congress, Barcelona, 16–20 avril 2010 :  (2010). 
769:[Abstract 139].
Crawford E.D. Switching from leuprolide to degarelix vs continuous degarelix treatment – effects on long-term prostate-specific antigen control 2010 AUA Annual Meeting, San Francisco May 29-June 3, 2010 :  (2010). 
e262138:[Abstract 670].
Gaast A. Cabazitaxel or mitoxantrone with prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel:Final results of a multinational phase III trial (TROPIC) 2010 ASCO Annual Meeting, Chicago, June 4–8, 2010 :  (2010). 
28:18s (suppl):abstr CRA 4508.
Shore N. Sipuleucel-T Active Cellular Immunotherapy for Metastatic, Castration-Resistant Prostate Cancer:results from the IMPACT trial 2010 EAU Annual congress :  (2010). 
16–20 avril Plenary #2.
Ivaz S., Lam W., Swallow T., Corbishley C.M., Perry M., Pilcher J., et al. A prospective study to evaluate the performance of ultrasound with or without fine-needle aspiration of inguinal nodes in patients with squamous cell carcinoma of the penis J Clin Oncol 2010 ;  28 : Abstract 250.
Graafland N.M., Leijte J.A., Valdes Olmos R.A., Hoefnagel C.A., Teertstra H.J., Horenblas S. Scanning with 18F-FDG-PET/CT for detection of pelvic nodal involvement in inguinal node-positive penile carcinoma Eur Urol 2009 ;  56 : 339-345 [cross-ref]
Schlenker B., Tilki D., Gratzke C., Seitz M., Reich O., Schneede P., et al. Intermediate-differentiated invasive (pT1 G2) penile cancer-oncological outcome and follow-up Urol Oncol 2009 ; 26[Epub ahead of print].
Rosen A.M., Drazer M.W., Eggener S.E. Global trends in testicular cancer incidence and mortality J Clin Oncol 2010 ;  28 : Abstract 259.
Bachner M., Zucali P., Horwich A., Oechsle K., Loriot Y., Flechon A., et al. 2-18fluoro-deoxy-d-glucose positron emission tomography (FDG-PET) for postchemotherapy seminoma residuals: A retrospective validation of the SEMPET trial J Clin Oncol 2010 ;  28 : Abstract 4581.
Tandstad T., Småland R., Klepp O.H., Cavallin-Stahl E., Stierner U., Laurell A., et al. Results from SWENOTECA V: A population-based protocol for seminomatous testicular cancer J Clin Oncol 2010 ;  28 : Abstract 4531.
Aparicio J., Robert L., Muro X.G., Guma J., Sanchez A., Margeli M., et al. Risk-adapted management of stage I seminoma: Results of the third Spanish Germ Cell Cancer Group study J Clin Oncol 2010 ;  28 : Abstract 4532.
Chung P.W., Daugaard G., Tyldesley S., Panzarella T., Kollmannsberger C.K., Gospodarowicz M.K., et al. Prognostic factors for relapse in stage I seminoma managed with surveillance: A validation study J Clin Oncol 2010 ;  28 : Abstract 4535.
Lewinshtein D., Porter C.R. Risk of secondary malignancy in patients with testicular cancer who have received radiation therapy J Clin Oncol 2010 ;  28 : Abstract 4537.






© 2011 
Elsevier Masson SAS. Tous droits réservés.